Investigating the genetic landscape of cancer in Jordan: a step toward personalized care.

Laith N Al-Eitan, Amneh H Tarkhan, Haneen O Ali, Maryam K Alasmar, Mansour A Alghamdi

Abstract readReview

In one paragraph

Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laith N Al-EitanDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan. lneitan@just.edu.jo.ORCID http://orcid.org/0000-0003-0064-0190

Amneh H TarkhanDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan.ORCID http://orcid.org/0000-0002-1035-0130

Haneen O AliDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan.ORCID http://orcid.org/0009-0006-4366-9304

Maryam K AlasmarDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan.ORCID http://orcid.org/0009-0005-5167-4544

Mansour A AlghamdiDepartment of Anatomy, College of Medicine, King Khalid University, 61421, Abha, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a leading cause of mortality worldwide, with genetic predispositions playing a key role in disease onset. This review assessed over 80 published genetic studies involving more than 3000 Jordanian cancer patients to explore the hereditary landscape of cancer in Jordan. Breast, colorectal, and lung cancers were the most studied, with BRCA1/2 and TP53 among the most frequently mutated genes. While somatic mutations such as KRAS and EGFR were commonly reported in tumor studies, our primary focus is on germline PSVs that may indicate population-specific genetic risks, including BRCA1 exon 11 mutations in breast cancer and p.Gly12Asp in KRAS for colorectal cancer. Unique or novel PSVs, particularly in BRCA2 and AKT1, were also reported, suggesting potential founder effects or region-specific genetic risks. These findings support integrating multigene panel testing and genetic counseling into national cancer prevention strategies to improve early detection and personalized care in Jordan.

Indexed as

Genetic Predisposition to DiseaseNeoplasmsPrecision MedicineGenetic TestingHumansJordanMutationCancerEarly screeningGeneticsGenetic testingJordan

Identifiers

PMID40604932

DOI10.1186/s40001-025-02799-7

PMCPMC12220200

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.